Study on Daratumumab for Treating Chemotherapy-Resistant Minimal Residual Disease in T Cell Acute Lymphoblastic Leukemia (T-ALL) | Clinical Trial

Study on Daratumumab for Treating Chemotherapy-Resistant Minimal Residual Disease in T Cell Acute Lymphoblastic Leukemia (T-ALL) | Clinical Trial | Right2Hope